Here are the 424B prospectus supplements from ALX Oncology Holdings Inc. (ALXO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ALXO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALXO filings page.
ALX Oncology Holdings is offering 76,979,112 shares of common stock and pre-funded warrants to purchase 18,574,120 shares, for gross proceeds of $150,000,000.12 before fees. Net proceeds are estimated at $140.4 million, mainly to fund clinical development of evorpacept and ALX2004, plus working capital.
The company preliminarily estimates $48.3 million in cash, cash equivalents and investments as of December 31, 2025 and notes that, absent this raise, there would have been substantial doubt about its ability to continue as a going concern. Investors in this offering face immediate dilution of $0.33 per share based on a $1.57 offering price.